Studies have shown the CD6-ALCAM pathway is overactive in the inflamed kidney and lungs of these patients. The potential of itolizumab to inhibit activation of multiple pro-inflammatory pathways ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback